Successful treatment with tocilizumab in a case of Cogan’s syndrome complicated with aortitis

REFERENCES

• Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS. Cogan syn-drome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore). 1980;59:426–41.
   PubMed Web of Science ®Google Scholar
• Gluth MB, Baratz KH, Matteson EL, Driscoll CL. Cogan syn-drome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc. 2006;81:483–8.
   PubMed Web of Science ®Google Scholar
• Grasland A, Pouchot J, Hachulla E, Bletry 0, Papo T, Vinceneux P. Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology (Oxford). 2004;43: 1007–15.
   Google Scholar
• Weyn T, Haine S, Conraads V. Cogan's syndrome with left main coronary artery occlusion. Cardiol J. 2009;16:573–6.
   Google Scholar
• Udayaraj UP, Hand MF, Shilliday IR, Smith WG. Renal involvement in Cogan's syndrome. Nephrol Dial Transplant. 2004;19:2420–1.
   PubMed Web of Science ®Google Scholar
• Raza K, Karokis D, Kitas GD. Cogan's syndrome with Taka-yasu's arteritis. Br J Rheumatol. 1998;37:369–72.
   PubMedGoogle Scholar
• Emilie D, Liozon E, Crevon MC, Lavignac C, Pother A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:17–24.
   PubMed Web of Science ®Google Scholar
• Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286–94.
   PubMed Web of Science ®Google Scholar
• Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006;45:545–8.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Suc-cessful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58: 1197–200.
   Google Scholar
• Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151–6.
   PubMed Web of Science ®Google Scholar
• Cogan DG, Grant WM. Keratitis due to N-butyl alcohol. Arch Ophthalmol. 1945;34:248.
   Google Scholar
• Kondo Y, Ito S, Ohi Y, Satou H, Hiraoka T, Tsuboi H, et al. Atypical Cogan's syndrome with aortitis. Intern Med. 2009; 48:1093–7.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Pikus A, Kaiser-Kupfer M, Fauci AS. Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids. Arthritis Rheum. 1981;24:501–3.
   Google Scholar
• Ghadban R, Couret M, Zenone T. Efficacy of infliximab in Cogan's syndrome. J Rheumatol. 2008;35:2456–8.
   Google Scholar
• Fricker M, Baumann A, Wermelinger F, Villiger PM, Helbling A. A novel therapeutic option in Cogan diseases? TNF-alpha blockers. Rheumatol Int. 2007;27:493–5.
   Google Scholar
• Beccastrini E, Emmi G, Squatrito D, Vannucchi P, Emmi L. Infliximab and Cogan's syndrome. Clin Otolaryngol. 2010;35: 441–2.
   PubMed Web of Science ®Google Scholar
• Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and eta-nercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132: 414–22.
   PubMed Web of Science ®Google Scholar
• Orsoni JG, Lagana B, Rubino P, Zavota L, Bacciu S, Mora P. Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report. Orphanet J Rare Dis. 2010;5:18.
   PubMed Web of Science ®Google Scholar
• Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13[Suppl 1]:S5.
   Google Scholar
• Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731–40.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus meth-otrexate monotherapy in patients with moderate to severe rheu-matoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.
   Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-con-trolled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21: 10–5.
   Google Scholar
• Seko Y, Sato 0, Takagi A, Tada Y, Matsuo H, Yagita H, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infil-trating cells in aortic tissue of patients with Takayasu's arteritis. Circulation. 1996;93:1788–90.
   Google Scholar
• Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70:1874–5.
   PubMed Web of Science ®Google Scholar
• Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum. 2012;64:866–75.
   PubMed Web of Science ®Google Scholar
• Scheel AK, Meller J, Vosshenrich R, Kohlhoff E, Siefker U, Muller GA, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis. 2004;63:1507–10.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum. 2009;60:1193-200.
   Google Scholar
• Blockmans D. PET in vasculitis. Ann N Y Acad Sci. 2011;1228:64–70.
   PubMed Web of Science ®Google Scholar
• Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49:826–37.
   PubMed Web of Science ®Google Scholar
• Carpenter DM, Thorpe CT, Lewis M, Devellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum. 2009;61:259–65.
   Google Scholar
• Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegen-er's). Arthritis Care Res (Hoboken). 2012;64:273–9.
   PubMed Web of Science ®Google Scholar
• Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Do-spinescu P, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford). 2010;49:1383–90.
   Google Scholar